



EAACI Hybrid Congress

Prague, Czech Republic

1-3 July



2022

📅 Friday 1 July

Scientific

Fri 1 Jul

09:00 - 10:30

Flash Talks on allergen immunotherapy in the clinic

Flash Talks

Chair : Milos Jesenak (Slovakia), Diana Silva (Portugal)

09:00
000122 **Exposure to allergen-specific immunotherapy in pregnancy and risk of congenital malformations and other adverse pregnancy outcomes**

Niki Mitselou (Sweden)

09:10
000443 **Consistent reduction of nasal and ocular symptoms in children treated with SQ grass or ragweed SLIT-tablet in randomised controlled trials**

Milos Jesenak (Slovakia)

09:20
000453 **Retrospective cohort study demonstrates the effects of allergen immunotherapy under real life conditions in house dust mite induced allergic rhinitis and asthma**

Ralph Mösges (Germany)

09:30
000562 **A first-in-human phase 2 dose-finding trial with grass pollen allergoids coupled to mannan in subcutaneous and sublingual immunotherapy. 1. Evaluation of safety**

Javier Subiza (Spain)

09:40
000605 **A first-in-human phase 2 dose-finding trial with grass pollen allergoids coupled to mannan in subcutaneous and sublingual immunotherapy. 2. Evaluation of efficacy using titrated nasal provocation test**

Javier Subiza (Spain)

09:50
001559 **Biomarkers of the Severity of Honeybee Sting Reactions and the Severity and Threshold of Systemic Adverse Events During Immunotherapy**

Peter Kopac (Slovenia)

10:00
000253 **Factors Predicting Response and Systemic Reactions of House Dust Mite Allergen Immunotherapy**

Rapisa Nantanee (Thailand)

10:10
000332 **IDENTIFICATION OF PROTEINS AND GLYCANS RELATED TO ALLERGY IN A MOUNTAIN CEDAR (*Juniperus ashei*) POLLEN EXTRACT**

Javier Alvarez (Spain)

10:20
001759 **Micro-arousals non-explained by respiratory events identified in the Polysomnography of a child allergic to dust mites suffering severe sleep disorders.Sleep disorders ceased three months after onset of allergen-specific immunotherapy with no recurrence**

Kalomoira Kefala (France)



Fri 1 Jul
11:15 - 12:45

Flash Talks on atopic dermatitis and environment

Flash Talks

Chair : Elizabeth Tham (Singapore), Margarida Goncalo (Portugal)

11:15
000363 **Atopic dermatitis-associated 6p21 variants regulate LOC100294145 expression and type 1 interferon signalling**
Wei Yi Teo (Singapore)

11:24
001508 **Autoreactive IgE antibodies in atopic dermatitis are associated with Type-2 diseases and environmental factors**
Fariza Badloe (Belgium)

11:33
000914 **Association between Diet Quality and Frequency based on Dietary Fats and Glycaemic Index Scores with the presentation of Atopic Dermatitis in Young Chinese Adults in Singapore and Malaysia**
Jun Jie Lim (Singapore)

11:42
000937 **Birth mode and the risk of atopic dermatitis in the first three years of life**
Sveinung Torsteinsen Hoel (Norway)

11:51
001449 **Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Not Responding Adequately to Dupilumab Treatment: An Analysis of Patient-Reported Outcomes in JADE EXTEND**
Michael Makris (Greece)

12:00
000079 **Detection of skin allergy biomarkers for point of care diagnosis of contact dermatitis**
Marine-Alexia Lefevre (France)

12:09
001197 **Evaluation of an operational automatic real-time pollen monitoring system: evidence from two sites in Augsburg, Germany**
Maria Plaza (Germany)

12:18
001372 **Maternal exposure to aeroallergens and perinatal outcomes**
Irene Bartha (United Kingdom)

12:27
001699 **Spatial transcriptomics combined with single-cell transcriptomics unravels the complex inflammatory cell network in atopic dermatitis**
Yasutaka Mitamura (Switzerland)

Fri 1 Jul
11:15 - 12:45 | **Flash Talks on hereditary angioedema**
Flash Talks

Chair : Joaquín Sastre (Spain), Werner Aberer (Austria)

11:15
000882 **Real-world Effectiveness and Safety of Lanadelumab in Patients With Hereditary Angioedema: Interim Findings From the ENABLE Study**
Tomas Andriotti (United States of America)

11:24
000038 **Patient perspectives on reproductive options for hereditary angioedema: a cross-sectional patient survey study**
Lauré Fijen (Netherlands)

11:33
000069 **Challenging primary angioedema with normal C1 inhibitor: novel insight from genotyping**
Giulia Costanzo (Italy)

11:42
000153 **The societal costs and disease burden of hereditary angioedema in the Netherlands**
Lauré Fijen (Netherlands)

11:51
000311 **Attack-free Status in Patients who Switched from Subcutaneous Lanadelumab to Oral Berotralstat**
Marc Riedl (United States of America)

12:00
000312 **Improvement in Quality of Life and Hereditary Angioedema (HAE) Attack Rates Observed in Patients Treated with Long-term Berotralstat in the APeX-2 Study**
Teresa Caballero (Spain)

12:09
000436 **Mutation-dependent selective effects during embryonic development indicated by inheritance pattern in hereditary angioedema**
Konrad Bork (Germany)

12:18
000655 **Berotralstat in real life setting for hereditary angioedema: a monocentric experience**
Delphine GOBERT (France)

12:27
000757 **Efficacy and safety of Tranexamic acid in attack prevention in a sub-group of nC1-INH-HAE-patients**
Amelie Hampel (Austria)

12:36
001063 **Real-World Effectiveness and Disease Management Data in European Patients With HAE on Long-term Prophylaxis With Lanadelumab: An Interim Analysis**
Markus Magerl (Germany)

Fri 1 Jul
14:15 - 15:45 | **Flash Talks on food allergy, urticaria and angioedema**
Flash Talks

Chair : Pasquale Comberiati (Italy), Jonathan Hourihane (Ireland)

14:15
000586 | **Health-Related Quality of Life Reported in Children, Teenagers, and Their Caregiver Proxy From Peanut Oral Immunotherapy Clinical and Follow-On Trials**
Audrey Dunn Galvin (Ireland)

14:25
000621 | **Significant Reduction of Major Egg Allergen Levels in Baked Foods**
Stephanie Filep (United States of America)

14:35
000306 | **Experience of a Madrid hospital with Cow's Milk Oral Immunotherapy**
Patricia Andrade Garbán (Spain)

14:45
000333 | **"The role of nasal challenge with Pru p 3 in the phenotyping of LTP-peach food allergy"**
Giovanna Araujo-Sánchez (Spain)

14:55
000703 | **Eosinophilia is associated with low cognitive function in children: a G21 cohort study**
Joao Rufo (Portugal)

15:05
000747 | **Impact of COVID-19 Vaccination on the course of Hereditary Angioedema**
Nida Öztop (Turkey)

15:15
000404 | **Treatment Satisfaction With Oral Immunotherapy for Peanut Allergy: Results From Clinical Trials**
Vibha Sharma (United Kingdom)

15:25
000181 | **Risk Factors for Home Epinephrine-Treated Reactions During Oral Immunotherapy for Food Allergy**
Liat Nachshon (Israel)

15:35
000603 | **Ligelizumab achieves complete response in chronic spontaneous urticaria patients with or without angioedema at baseline: A composite score evaluation**
Marcus Maurer (Germany)

Fri 1 Jul
14:15 - 15:45 | Flash Talks on drug allergy
Flash Talks

Chair : Martina Koziar Vašáková (Czech Republic), Marina Atanaskovic-Markovic (Serbia)

14:15
001501 **CD203c, a reliable and suitable activation marker in basophil activation test to evaluate immediate hypersensitivity reactions to betalactams**
Ruben Fernandez-Santamaria (Spain)

14:23
000278 **Drug hypersensitivity in cystic fibrosis – low frequency of anaphylaxis in 16910 antibiotic courses**
Theo Gülen (Sweden)

14:31
001056 **Deconstructing adverse reactions to amoxicillin-clavulanic acid**
Natalia Patricia Freundt-Serpa (Spain)

14:39
001142 **Hypersensitivity reactions to iron products: 10-year experience in a Portuguese Tertiary Centre**
Cláudia Varandas (Portugal)

14:47
001434 **Basophil activation test as a useful diagnostic tool for phenotyping hypersensitivity reactions to chemotherapy**
Ruben Fernandez-Santamaria (Spain)

14:55
001798 **Severe sleep disorders, mild Obstructive Sleep Apnoea, severe exercise-induced asthma and severe eczema in a child allergic to Alternaria Alternata. Specific-Allergen Immunotherapy for Alternaria Alternata leads to cease of all clinical signs**
Kalomoira Kefala (France)

15:03
001147 **Are sulfamethoxazole-trimethoprim intradermal tests really useful?**
Ricardo Moço Coutinho (Portugal)

15:11
001801 **Prospective, multicenter validation of a data-driven drug provocation test to beta-lactams**
Omar Al Ali (France)

15:19
000112 **Gadolinium contrast-based agents: use in real-life conditions after negative allergy work-up by skin testing**
Audrey Kamga (France)

15:27
001767 **Exonic variants (SNPs and INDELS) exclusive for amoxicillin- and clavulanic-allergic patients could help to prevent allergic reactions**
Ruben Fernandez-Santamaria (Spain)

Fri 1 Jul
16:15 - 17:45 | Flash Talks on allergy management
Flash Talks

Chair : Pablo Rodríguez del Río (Spain), Thomas Eiwegger (Austria)

16:15
100166 **Validation of a non-invasive method for specific IgA profiling using an allergen microarray in fecal samples of premature infants**

Joana Vitte (France)

16:22
100105 **Positive regulation of innate immune response by miRNA, let-7a-5p, which upregulated in plasma of both Atopic dermatitis with/without Atopic keratoconjunctivitis**

Mayumi Ueta (Japan)

16:29
100125 **Jun o 1, a novel allergen from Juniperus oxycedrus pollen**

Jose Fernando Cantillo (Spain)

16:36
100158 **Comparison of three serum IgE specific assays in cashew sensitization**

Caroline Klingebiel (France)

16:43
100221 **Should we consider Euroglyphus maynei as a species with clinical relevance in house dust mites' allergic patients?**

Naser Aali Mohamed (Spain)

16:50
100163 **Randomized, proof of concept clinical trials for therapeutic efficacy and safety of the high intensity focused ultrasound stimulators in patients with severe nasal congestion by inferior turbinate hypertrophy**

Sun A Han (Korea, Republic of)

16:57
100111 **Thresholds of over tenfold the original tolerated food allergen are achieved in Oral Immunotherapy**

Ella Parsons (United States of America)

17:04
100133 **Immune response to mosquito allergens could be associate with cross-reactive bee venom components: The myth of the Bee-Mosquito Syndrome**

Carina Uasuf (Italy)

17:11
100197 **Pharmacokinetic, pharmacodynamic and safety comparative phase 1/2 study between FMXIN002, a fast acting, dry powder epinephrine intra-nasal formulation, and IM epinephrine under simulated allergic reaction conditions**

Yuval Tal (Israel)

17:18
100142 **Early introduction of multi-allergen mixture is safe and efficacious for food allergy prevention**

Antonia Zoe Quake (United States of America)

17:25
100259 **The Clinical Significance of IgE Ratios in Patients with Suspected Egg Allergy**

Ana Reis Ferreira (Portugal)

17:32
100019 **Efficacy and Safety of Lanadelumab in Pediatric Patients Aged 2 to <12 years With Hereditary Angioedema: Results From the Open-Label, Multicenter Phase 3 SPRING Study**

Marcus Maurer (Germany)

 Saturday 2 July

Scientific

Sat 2 Jul
08:30 - 10:00 | Flash talks on molecular allergology
Flash Talks

Chair : Paolo Matricardi (Germany), Cristina Gomez-Casado (Germany)

08:30
000170 | **Two new insights in human anaphylaxis: personalized diagnostic approach and molecular evaluation of extravasation**
Emilio Nuñez-Borque (Spain)

08:42
000991 | **Optimizing sesame seed protein extraction protocols for a better molecular characterization of sesame allergic patients**
Laura Mondéjar-Traveria (Spain)

08:54
000349 | **Management of patients with seasonal allergic rhinitis: Diagnostic consideration of sensitization to non-frequent pollen allergens**
Conny Höflich (Germany)

09:06
000592 | **Childhood grass pollen-related allergen components sensitization does not increase asthma risk at age of 10 – evidence from the Generation XXI birth cohort**
Mariana Farraia (Portugal)

09:18
001548 | **Mast cell activation test can evaluate patients with inconclusive results of the basophil activation test in the diagnosis of Hymenoptera venom allergy**
Luka Dejanović (Slovenia)

09:30
000163 | **The basophil activation test has high reproducibility and is well integrated in the clinical decision-making process**
Alexandra F. Santos (United Kingdom)

09:42
000606 | **Allergy to Capsicum genus : involvement of Cap a 7, a member of the Gibberellin-regulated protein allergen family**
Pascal Poncet (France)

Sat 2 Jul
10:30 - 12:00 | Flash Talks on urticaria and angioedema
Flash Talks

Chair : Anna Sediva (Czech Republic), Knut Brockow (Germany)

10:30
000916 | **More patients achieve absence of angioedema with remibrutinib (LOU064) than placebo: Results from a dose-finding Phase 2b study**
Marcus Maurer (Germany)

- 10:38**
000952 **Identification of Circulating IgG Autoantibody to Heat Shock Protein-10 as a Potential Biomarker for Chronic Spontaneous Urticaria**
Young-Min Ye (Korea, Republic of)
-
- 10:46**
001012 **Long term control of urticaria disease activity with ligelizumab in patients with chronic spontaneous urticaria: data from the Phase 2b extension study**
Jonathan Bernstein (United States of America)
-
- 10:54**
001806 **Comparative economic burden of chronic spontaneous urticaria, psoriasis and atopic dermatitis in five European countries (France, Germany, Italy, Spain, and United Kingdom)**
Maria-Magdalena Balp (Switzerland)
-
- 11:02**
001098 **Moderate to severe chronic spontaneous urticaria has a similar quality of life impact to moderate to severe plaque psoriasis: results from the data42 platform to repurpose clinical trial data**
Ivan Nikolaev (Switzerland)
-
- 11:10**
000781 **Systems biology-based mechanistic models support the centrality of mast cell activation and the IgE-FcεRI axis in chronic spontaneous urticaria**
Jessica Gómez (Spain)
-
- 11:18**
001249 **Efficacy of the Oral Plasma Kallikrein Inhibitor, KVD900, by Attack Location in a Phase 2 Clinical Trial in Patients with Hereditary Angioedema**
Emel Aygören-Pürsün (Germany)
-
- 11:26**
000313 **96 Weeks of Treatment with Bertralstat Consistently Decreases the Use of Injectable On-Demand Medication to Treat Hereditary Angioedema (HAE) Attacks: Analysis from APeX-2**
Laurence Bouillet (France)
-
- 11:34**
001345 **Patient-Reported Outcomes (PROs) in Patients with Hereditary Angioedema Receiving Lanadelumab: Interim Findings from the ENABLE Study**
Markus Magerl (Germany)
-
- 11:42**
001025 **Challenges in the Management of Mastocytosis – a worldwide Survey (MAMAS)**
Polina Pyatilova (Germany)
-
- 11:50**
000623 **Effect of avapritinib on skin disease burden in patients with advanced systemic mastocytosis (AdvSM): A novel, artificial intelligence (AI)-based technology**
Karin Hartmann (Switzerland)

Sat 2 Jul
13:30 - 15:00 | **Flash Talks on asthma and biologicals**
Flash Talks

Chair : Wojciech Feleszko (Poland), Andre Moreira (Portugal)

13:30 **Functional polymorphisms in COPZ1 gene associated with allergic asthma in a Singapore**

- 001073 **Chinese population**
Praneeth Malipeddi (Singapore)
-
- 13:37
001109 **EDN levels in infants and preschoolers and in subgroups with atopy and asthma: A population-based observational study**
Martin Färdig (Sweden)
-
- 13:44
000971 **Diacylgalactosyldiacylglycerols from grass pollen prime the development of allergic airway inflammation**
Nestor González Roldán (Germany)
-
- 13:51
001232 **MV130, a whole heat-inactivated polybacterial mucosal vaccine, impairs airway inflammation in a HDM-induced eosinophilic asthma model**
Ana Carmen Sevilla Ortega (Spain)
-
- 13:58
000897 **The effectiveness of biologic agents on nasal polyps in patients with asthma : A retrospective multicenter real-life study**
Meryem Demir (Turkey)
-
- 14:05
000323 **Sinonasal and respiratory outcomes of EGPA patients receiving 100 mg Mepolizumab in real-life clinical practice: 1-year follow up study**
Ozge Can Bostan (Turkey)
-
- 14:12
001090 **One-year longitudinal results of real-world prospective observational cohort corroborates efficacy and safety of dupilumab for severe Chronic Rhinosinusitis with Nasal Polyps**
Rik van der Lans (Netherlands)
-
- 14:19
001146 **No evidence of increased risk of cancer with anti-IL-5 and anti-IL-4Ra biologicals: a disproportionality analysis of the WHO's pharmacovigilance database**
Diogo Mota (Portugal)
-
- 14:26
000787 **Evaluation of Benralizumab effectiveness in asthmatic patients affected from EGPA**
Andrea Giovanni Ledda (Italy)
-
- 14:33
001013 **Generation of omalizumab variants with enhanced disruptive efficacy for active desensitization**
Alexander Eggel (Switzerland)
-
- 14:40
001058 **Real-world impact of mepolizumab on the oral corticosteroid freedom component of clinical remission in severe asthma: International, prospective REALITI-A study at 1 year**
Liam Heaney (United Kingdom)
-
- 14:47
000468 **An epigenetic marker from the Phospholipase A2 Group XIIA gene associates with fractional exhaled nitric oxide levels in pediatric asthma**
Mario Martín Almeida (Spain)
-
- 14:54
001503 **Severe Annual Exacerbation Rate and Lung Function in Fungal Sensitized and Fungal not Sensitized Patients With Severe Asthma: Post hoc Analysis of LIBERTY ASTHMA QUEST Study**

Xavier Soler (United States of America)

Sat 2 Jul
13:30 - 15:00 | **Flash Talks on allergen immunotherapy**
Flash Talks

Chair : Enrico Heffler (Italy), Mattia Giovannini (Italy)

13:30
000391 **Ara h 2-expressing cucumber mosaic virus-like particle (VLP): A new generation of hypoallergenic therapeutic vaccine for peanut allergy**
Janice A Layhadi (United Kingdom)

13:38
000400 **Ara h 2-expressing virus-like particle (VLP) induces IL-10-producing B regulatory cells in peanut-allergic individuals: Novel therapeutic candidate for peanut allergy**
Mohamed Shamji (United Kingdom)

13:46
000394 **Induction of type 1 dendritic cell-associated genes by Ara h 2-expressing virus-like particle (VLP): A novel immune modulatory approach for peanut allergy**
Mohamed Shamji (United Kingdom)

13:54
000398 **Modulation of Th2, Th2A, T follicular helper cells and induction of Th1 cells by Ara h 2-expressing virus-like particles (VLP): A novel therapeutic vaccine candidate for peanut allergy**
Janice A Layhadi (United Kingdom)

14:02
000415 **The impact of the COVID-19 pandemic on hymenoptera venom immunotherapy: experience of an allergy department**
Daniela Brandão Abreu (Portugal)

14:10
000451 **Cluster schedule with a maximum concentration cat-dander extract**
R Paulauskas-Vasaitis (Spain)

14:18
000541 **Real-world costs and health care resource use from a large German insurance claims database: Results from the REACT (Real world effectiveness in allergy immunotherapy) study**
Benedikt Fritzsching (Germany)

14:26
001105 **Safety, feasibility and effectiveness of low-dose oral immunotherapy in young children with multiple food allergies**
Lieke Barten (Netherlands)

14:34
001386 **Safety comparison of regular- and rush build-up oral immunotherapy protocols used in young children**
Juliëtte Kuiken (Netherlands)

14:42
001734 **Safety of subcutaneous immunotherapy with carbamylated allergoids as assessed using a pharmacovigilance database**
Franco Frati (Italy)

14:50
000066**Successful Oxaliplatin Desensitization After Umaliizumab Administration**
ZEYNEP YEGİN KATRAN (Turkey)

Sat 2 Jul

15:30 - 17:00

Flash Talks on rhinosinusitis and nasal polyps

Flash Talks

Chair : Gulfem Celik (Turkey), Ludger Klimek (Germany)

15:30
001818 **Mechanisms of nasal hyperreactivity in type 2 chronic upper airway inflammation**
Wout Backaert (Belgium)**15:41**
000558 **Investigating diverse features of pediatric rhinitis based on cluster analysis: Allergic Rhinitis Cohort Study for Kids (ARCO-Kids Study)**
Jin-A Park (Korea, Republic of)**15:52**
000979 **Role of siblings in the development of allergic rhinitis: a systematic review and meta-analysis**
Daniil Lisik (Sweden)**16:03**
000674 **Abatacept (Cytotoxic T lymphocyte Antigen 4-fragment crystallizable) treatment suppressed disease activity in a mouse model of eosinophilic CRS**
Jae-Yoon Kang (Korea, Republic of)**16:14**
001512 **PAF receptor and Lyso-PAF isoforms are highly expressed in CRSwNP tissues than in healthy nasal mucosa**
Joaquim Mullol (Spain)**16:25**
001621 **Inotodiol suppresses allergic inflammation in allergic rhinitis mice**
Min Su Kim (Korea, Republic of)**16:36**
001101 **Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison**
Claus Bachert (Belgium)**16:47**
001810 **IL-17A-producing Sinonasal MAIT Cells in Patients with Chronic Rhinosinusitis with Nasal Polyps**
Min-Seok Rha (Korea, Republic of)

Sat 2 Jul
15:30 - 17:00

Flash Talks on primary immunodeficiencies, infection and allergy
Flash Talks

Chair : Milena Sokolowska (Switzerland), Wojciech Feleszko (Poland)

15:30
001128 **Early life dietary osteopontin supports protection against viral respiratory infection**
Cheong Kwong Chung (Switzerland)

15:41
001283 **The synthetic cannabinoid agonist WIN55212-2 improves epithelial barrier impairment caused by rhinovirus infection and type 2 inflammation**
Mario Perez-Diego (Spain)

15:52
001549 **Clinical, Immunological, and Genetic Features of a Mexican Cohort of Patients with DOCK8 Deficiency**
Eduardo Liquidano-Perez (Mexico)

16:03
001571 **Prevalence of T-LGL (large granular lymphocyte) expansion and T-LGLL in COVID patients at University Hospital Ca' Foncello Treviso**
Patrick Bez (Italy)

16:14
001916 **Delayed induction of inflammatory and anti-viral response of Microvascular Lung Endothelium during Human Coronavirus 229E infection**
Robert Szewczyk (Poland)

16:25
001145 **Validation of calculated globulin (CG) as a screening test for antibody deficiency in Turkish adult patients**
Osman Yegit (Turkey)

16:36
001771 **Determining helminth-induced serum factors and their anti-viral effects in a mouse-model of RSV infection**
Karla Berry (United Kingdom)

16:47
100124 **Immunological and Exploratory Outcomes from a Phase 3, Placebo-Controlled, Randomized Clinical Trial of PI3K Delta Inhibitor Leniolisib in Patients with Activated PI3K Delta Syndrome (APDS/PASLI)**
Virgil A. Dalm (Netherlands)

Sat 2 Jul
17:30 - 19:00 | **Flash talks on clinical immunology**
Flash Talks

Chair : Aurelie Poli (Luxembourg), Tae-Bum Kim (Korea, Republic of)

17:30
000961 | **A mechanistic skin immunology model for the support of atopic dermatitis clinical trial design and biomarker programs**
Théo Galland (France)

17:41
001704 | **Multi-omic phenotyping of apheresis-purified platelets**
Carmela Pablo-Torres (Spain)

17:52
000425 | **Functional 6p21.32 variants associate with sensitization against inhalant allergens in Singapore**
Yang Yie Sio (Singapore)

18:03
001529 | **Synergistic effect of amoxicillin and LPS can improve diagnosis of amoxicillin IgE-mediated hypersensitivity reactions by BAT**
Cecilia Frecha (Spain)

18:14
000369 | **A new strategy for the detection of allergen-specific IgE+ memory and plasmablasts/plasma cells**
Mohammed Zghaebi (Austria)

18:25
001878 | **Investigation of miR146a, miR155 in patients with reactive arthritis induced by Chlamydia trachomatis and Epstein-Barr virus**
Marta Lomikowska (Ukraine)

18:36
001204 | **Usefulness of basophil activation test in chemotherapeutic agents allergy: comparison with skin tests**
Jenny Tatiana Verdesoto (Spain)

Sat 2 Jul
17:30 - 19:00 | **Flash Talks on mechanisms of food allergy**
Flash Talks

Chair : Kitty Verhoeckx (Netherlands), Vanesa Esteban (Spain)

- 17:30**
000274 | **Mustard major allergen Sin a 1 is able to induce epithelial inflammation and drives immune polarization in human moDC/T-cell cultures**
Cristina Bueno-Díaz (Netherlands)
-
- 17:40**
000295 | **A novel Virus-like particle platform for the treatment of peanut allergy: mechanistic insights**
Pascal Krenger (Switzerland)
-
- 17:50**
000734 | **The synthetic cannabinoid WIN55212-2 impairs peanut allergic-sensitization and promotes the generation of regulatory T cells**
Alba Angelina (Spain)
-
- 18:00**
000933 | **Mouse blood protein survives degradation in Ixodes ricinus ticks after molting and upon starvation up to 6 months**
Neera Chakrapani (Luxembourg)
-
- 18:10**
000990 | **Quantifiable upper gastro-intestinal symptoms and basophil activation in a Brown Norway rat model of peanut allergy**
Jeppe Madura Larsen (Denmark)
-
- 18:20**
001084 | **Egg and milk consumption during late pregnancy and food reactions in grandchildren**
Ida Mogensen (Sweden)
-
- 18:30**
001310 | **Adjuvant-free mouse model of oral allergic sensitization to egg is mediated by IgG**
Sara Benedé (Spain)
-
- 18:40**
001432 | **Efficacy of peanut oral immunotherapy between children and adults in a longitudinal study**
R. Sharon Chinthrajah (United States of America)
-
- 18:50**
001313 | **Molecular sensitization profile in peach allergic patients in a well-defined area**
Laura Martín Pedraza (Spain)

Sun 3 Jul
11:15 - 12:45 | Flash talks on food allergy
Flash Talks

Chair : Arnon Elizur (Israel), Carmen Panaitescu (Romania)

11:15
000219 **Cutaneous sensitisation to gluten hydrolysate in both absence and presence of AD drives changes in local and systemic T cell phenotype composition in a rat food allergy model**
Jeppe Madura Larsen (Denmark)

11:23
001070 **Complementary feeding and allergic diseases in childhood in the ELFE nationwide cohort**
Tania Adam (France)

11:31
000778 **The risk factors affecting the severity of anaphylaxis; A multicenter study**
Osman Yegit (Turkey)

11:39
001143 **Peach allergy across Europe and Japan: distribution of allergen sensitization patterns and prediction of severity**
Emily Kallen (Netherlands)

11:47
001161 **Evaluation of Anaphylaxis Developed During Oral Food Challenge and Drug Provocation Tests in the Pediatric Allergy Clinic**
Irem Turgay Yagmur (Turkey)

11:55
001228 **A mucin-degrading gut bacterium modulates food allergy sensitization in a diet-dependent manner**
Marie Boudaud (Luxembourg)

12:03
001710 **Toward the diet planning with artificial intelligence for children with food allergies**
Minyoung Jung (Korea, Republic of)

12:11
000351 **Soybean Anaphylaxis and LTP Syndrome**
Soledad San Roman Sirvent (Spain)

12:19
000687 **Unexpected peanut anaphylaxis**
Arantza Vega Castro (Spain)

12:27
000563 **Diagnosis of wheat-dependent exercise-induced anaphylaxis in ω -5 gliadin-negative patients**
Valentina Faihs (Germany)

12:35
001140 **Dupilumab Improves Histological Outcomes and Normalizes Disease and Type 2 Inflammation Transcriptome Signatures in Adult and Adolescent Patients With Eosinophilic Oesophagitis: Results From the 3-Part Phase 3 LIBERTY EoE TREET Study**
Alain M. Schoepfer (Switzerland)

Sun 3 Jul
11:15 - 12:45 | **Flash Talks on COVID and allergy**
Flash Talks

Chair : Farah Hannachi (Luxembourg), Riccardo Castagnoli (Italy)

11:15
100242 **STAR-0215, a long-acting monoclonal antibody plasma kallikrein inhibitor in development for treatment of HAE, demonstrates sustained functional inhibition in subcutaneously dosed cynomolgus monkeys**
Pradeep Bista (United States of America)

11:22
100045 **FENO is not an atopy biomarker during SARS-CoV-2 infection**
Diana Betancor (Spain)

11:29
100109 **Safety of COVID-19 vaccine challenge in patients with immediate hypersensitivity reactions to prior doses - A multicentre cohort study**
Joseph De Luca (Australia)

11:36
100130 **Multi-Dimensional Correlates of COVID-19 Protection and Severity in Vaccine-Breakthrough**
Mehmet Goekkaya (Germany)

11:43
100169 **Late hypersensitivity reactions to the BNT162b2 SARS-CoV-2 vaccine are linked to delayed skin sensitization and prior exposure to Hyaluronic acid**
Ramit Maoz-Segal (Israel)

11:50
001102 **A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 µg Once Daily on Growth Velocity in Prepubertal Children with Asthma**
Jodie Crawford (United Kingdom)

11:57
000039 **Artificial Intelligence and Transfer Learning for Spirometry Quality Control in School Aged Children**
Carla Martins (Portugal)

12:04
000142 **IgG sensitization profiles determined by allergen microarray in neonatal faecal samples and the occurrence of allergy during the first year of life**
Joana Vitte (France)

12:11
000202 **Genotype markers for personalized predictive diagnostics of atopic disorders` phenotypes in children**
VOLODYMYR DYTIATKOVSKYI (Ukraine)

12:18
000423 **Predicting of house dust mite positive nasal provocation test using skin prick test in rhinitis children**
Natchanun Klangkalya (Thailand)

12:25
000561 **Timing of food introduction in relation to allergy diagnosis during the first year of life: results from a Swedish birth cohort**



12:32
100084

Separating the effect of patient baseline characteristics from the effect of treatment on exacerbation risk: a model-based analysis of time to first exacerbation in moderate and severe asthma

Ian Pavord (United Kingdom)

12:39
100067

IgE-mediated cross-reactivity between BNT162b2, polyethylene glycol and polysorbate 80 in patients with dual excipient allergy

Rik Schrijvers (Belgium)
